Malignant astrocytoma in elderly patients: Where do we stand?

Ghazaleh Tabatabai*, Roger Stupp, Wolfgang Wick, Michael Weller

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Summary Current standard of care for elderly patients with malignant astrocytoma involves a treatment strategy based on the MGMT gene promoter methylation status. The role of combined radiotherapy and TMZ chemotherapy and a potential role for the addition of anti-VEGF therapy to radiotherapy are currently addressed in ongoing trials. The lack of favorable prognostic factors in tumor tissue might in part explain the poorer clinical outcome of elderly patients.

Original languageEnglish (US)
Pages (from-to)693-700
Number of pages8
JournalCurrent Opinion in Neurology
Issue number6
StatePublished - Dec 2013


  • Clinical trial
  • Elderly patients
  • Malignant astrocytoma
  • Molecular signature

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Malignant astrocytoma in elderly patients: Where do we stand?'. Together they form a unique fingerprint.

Cite this